ArticleClinical pharmacology and therapeutics2026
Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer.
Emmanuel Chigutsa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.